Drugs / hrINF-alpha
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00024518 | Sep 2001 → Sep 2008 | type 1 diabetes mellitus | The University of Texas Health Science Center, Houston | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hrINF-alpha | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00024518 ↗ |
| Modality | Protein / enzyme biologic | “OBJECTIVE: To evaluate the safety and efficacy of ingested human recombinant interferon-alpha (hrIFN-alpha) for preservation of beta-cell function in young patients with...” PMID 19564474 ↗ Jul 2009 |